Histide — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Histide is a private, Paris-based biotech developing an innovative extracellular therapeutic platform centered on Cell Recoding Molecules (CRM). This approach seeks to treat diseases by providing precise extracellular signals to reprogram cell behavior without genetic modification, positioning it as a potential breakthrough for untreatable conditions. The company is pre-clinical and pre-revenue, building its intellectual property portfolio and pipeline with a leadership team combining deep scientific and IP expertise. Key validation includes a published Nature paper on stem cell differentiation mechanisms.

OncologyRegenerative Medicine

Technology Platform

Platform for discovering non-mutagenic, extracellular Cell Recoding Molecules (CRM) that modulate cell fate by interfacing with native signal transduction pathways, avoiding genetic modification.

Opportunities

The platform targets a wide range of untreatable diseases with a non-mutagenic approach, potentially offering a safer alternative to gene editing.

Applications span pharmaceuticals, medical devices, and cosmetics, creating multiple commercial pathways.

Validation through a Nature publication provides strong scientific credibility for partnership discussions.

Risk Factors

The novel scientific approach is unproven and faces high technical risk in translating extracellular signaling into effective drugs.

As a pre-revenue, pre-clinical company, it is dependent on raising significant capital.

The intellectual property strategy is critical but may face challenges in a competitive field.

Competitive Landscape

Competes with established cell and gene therapy companies (e.g., CRISPR Therapeutics, Bluebird Bio) and broader biopharma firms targeting oncology and regeneration. Differentiation lies in the extracellular, non-mutagenic mechanism, but it must prove efficacy against more advanced modalities. Other startups in cellular reprogramming and microenvironment modulation are also potential competitors.

More companies in Biologics / Biosimilars →More companies in France →